Company Name Scioderm
Mailing Address 1007 Slater Road Durham, NC 27703 USA
Company Description The core business focus of Scioderm is the development of innovative dermatological drugs. Our strategy is to in-license or acquire early to mid-stage pharmaceutical products with the intent to develop the topical products.
M&A Terms The $229 million upfront payment for Scioderm consists of $125 million in cash and $104 million in Amicus stock. Amicus will pay Scioderm shareholders another $361 million in cash or stock upon achievement of certain clinical and regulatory milestones and $257 million in cash or stock upon achievement of certain sales milestones.